MGX

Business Context and Reporting Period

Company: Metagenomi Therapeutics, Inc. (MGX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Metagenomi is an in vivo genome editing company developing curative genetic medicines. In Q1 2026, the company changed its name from Metagenomi, Inc. to Metagenomi Therapeutics, Inc. to reflect a strategic evolution focused on advancing later-stage preclinical programs. The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Note: Total Cash, Cash Equivalents & Marketable Securities for Q1 2026 is calculated as Cash ($25,306) + Available-for-sale securities ($114,856) + Restricted Cash ($4,393) = $144,555. Management states $140.2 million is available to fund operations, likely excluding restricted cash or specific securities.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased by $2.9 million (70%) year-over-year. This was driven by a $2.7 million decrease in revenue from the Ionis Pharmaceuticals agreement and the cessation of revenue from the Affini-T agreement following its termination in September 2025.
• Expense Reduction: Total operating expenses decreased by $6.1 million (19%). Research and development expenses dropped $5.8 million, primarily due to reduced employee-related expenses ($3.3 million) and supplies/services ($1.1 million) following a 25% workforce reduction announced in November 2025.
• Net Loss Improvement: Net loss narrowed by $2.0 million to $23.1 million, reflecting the greater reduction in operating expenses compared to the decline in revenue.
• Liquidity Position: Cash and cash equivalents decreased by $16.4 million from the beginning of the period, primarily due to net cash used in operating activities of $21.2 million, partially offset by net cash provided by investing activities of $4.0 million (net maturities of marketable securities).

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Liquidity: Management believes existing cash, cash equivalents, and available-for-sale marketable securities ($140.2 million) are sufficient to fund operations for at least the next 12 months from the date of issuance.
• Pipeline Progress: The company is on track to submit an Investigational New Drug (IND) application for its lead candidate, MGX-001 (Hemophilia A), in Q4 2026, with clinical trials expected to initiate in 2027. Preclinical data in non-human primates demonstrated curative Factor VIII activity.
• Strategic Focus: The company has reprioritized its pipeline to focus on high-value programs with well-understood biology and clear regulatory pathways.

Risks and Contingencies:

• Securities Litigation: A class action lawsuit (Vreeland v. Metagenomi Inc. et al.) alleges misleading statements regarding a collaboration with Moderna. The court granted-in-part and denied-in-part the defendants' motion to dismiss in March 2026. The company cannot estimate the potential loss.
• Capital Needs: The company has incurred significant losses since inception and expects to continue doing so. It will require substantial additional funding to advance clinical trials and commercialize products. It has an "At-The-Market" (ATM) sales agreement with $75.0 million capacity, though no shares have been sold under it as of March 31, 2026.
• Contract Modifications: On April 1, 2026, the Ionis collaboration agreement was modified to extend research services for one target and discontinue the exploratory research plan. This may result in a one-time non-cash reversal of previously recognized revenue in Q2 2026.
• Regulatory & Development Risks: As an early-stage company with no approved products, the company faces significant risks related to the novel nature of genome editing, regulatory approval timelines, and the ability to raise future capital.

Key Facts for Investor Verification

• Cash Runway: Verify the $140.2 million liquidity figure and the 12-month runway estimate against current burn rates and potential contract modifications with Ionis.
• Ionis Revenue Impact: Monitor Q2 2026 filings for the quantitative impact of the April 1, 2026 contract modification, specifically any revenue reversal.
• Legal Exposure: Track the status of the Vreeland securities class action lawsuit, as the outcome could result in significant damages or settlement costs.
• MGX-001 Timeline: Confirm the Q4 2026 IND submission timeline for the lead Hemophilia A candidate, as delays could impact future financing needs.
• ATM Utilization: Monitor if the company utilizes its $75.0 million ATM facility to raise capital, which could lead to shareholder dilution.